Pürin ve Pirimidin Metabolizması Bozuklukları
Özet
Pürin ve pirimidin metabolizması bozuklukları, enzim yetmezlikleri veya süperaktiviteleri sonucu ortaya çıkan, geniş bir klinik spektruma sahip genetik hastalıklardır. Bu bozukluklar sıklıkla nörolojik, immünolojik, hematolojik ve renal semptomlarla kendini gösterir. Tanı genellikle kapsamlı enzim kinetik çalışmaları ve genetik analizlerle konulurken, tedavi seçenekleri sınırlı olup sıklıkla destekleyici yaklaşımları içerir. Metabolik dengesizliklerin erken teşhisi, özellikle şiddetli nörolojik seyreden vakalarda klinik yönetimi belirlemektedir.
Purine and pyrimidine metabolism disorders are a broad group of genetic conditions caused by enzymatic deficiencies or superactivity that manifest with a wide clinical spectrum. These disorders frequently present with significant neurological, immunological, hematological, and renal findings. Diagnosis typically requires comprehensive enzymatic and genetic analysis, as therapeutic options remain limited and often depend on supportive care. Early detection of metabolic imbalances is crucial, particularly in cases involving severe neurological progression.
Referanslar
Marie S, van den Berghe G and Vincen MF. Disorders of Purine and Pyrimidine Metabolism. In: Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases. Diagnosis and Treatment, 6th ed. Berlin Heidelberg: Springer-Verlag; 2016: 495-513.
Phosphoribosylpyrophosphate Synthetase Superactivity. de Brouwer APM, Duley JA,Christodoulou J.2008 Sep 23 [updated 2015 Dec 17]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.
Mittal R, Patel K, Mittal J et al. Association of PRPS1 Mutations with Disease Phenotypes. Dis Markers. 2015;2015:127013.
Balasubramaniam S, Duley JA, Christodoulou J. Inborn errors of purine metabolism: clinical update and therapies. J Inherit Metab Dis. 2014;37(5):669-686.
Synofzik M, Müller vom Hagen J, Haack TB et al. X-linked Charcot-Marie-Tooth disease, Arts syndrome, and prelingual non-syndromic deafness form a disease continuum: evidence from a family with a novel PRPS1 mutation. Orphanet J Rare Dis 2014;9:24–31.
Andelman-Gur MM, Saitsu H, Matsumoto N et al. Myoclonic tremor status as a presenting symptom of adenylosuccinate lyase deficiency. Eur J Med Genet. 2020; 63(12):104061
Jurecka A, Zikanova M, Kmoch S, Tylki-Szymańska A. Adenylosuccinate lyase deficiency. J Inherit Metab Dis. 2015;38(2):231-42.
Banerjee A, Bhatia V, Didwal G, Singh AK, Saini AG ADSL Deficiency - The Lesser-Known Metabolic Epilepsy in Infancy. Indian J Pediatr. 2021;88(3):263-265.
Mouchegh K, Zikanova M, Hoffmann GF et al. Lethal fetal and early postnatal presentation of adenylosuccinate lyase deficiency: observation of 6 patients in 4 families. J. Pediatr 2007;150:57-61.
Mierzewska H, Schmidt-Sidor B, Jurkiewicz E et al. Severe encephalopathy with brain atrophy and hypomyelination dueto adenylosuccinate lyase deficiency–MRI, clinical, biochemical and neuropathological findings of Polish patients. Folia Neuropathol 2009;4:314-320.
Jurecka A, Zikanova M, Tylki-Szymanska A et al. Clinical, biochemical and molecular findings in seven Polish patients with adenylosucinate lyase deficiency. Mol Gen Metab 2008;94:435–442.
Laikind PK, Seegmiller JE, Gruber HE. Detection of 5’-phos-phoribosyl-4-(N-succinylcarboxamide)-5-aminoimidazole in urine by use of the Bratton-Marshall reaction: identification of patients deficient in adenylosuccinate lyase activity. Anal Biochem 1986;156:81–90.
Ito T, Kuilenburg v ABP, Bootsma AH et al. Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips. Clin Chem 2000;46:445-452.
Hartmann S, Okun JG, Schmidt C et al. Comprehensive detection of disorders of purine and pyrimidine metabolism by HPLC with electrospray ionization tandem mass spectrometry. Clin Chem 2006;52:1127-1137.
Van Werkhoven MA, Duley JA, McGown I et al. Early diagnosis of adenylosuccinate lyase deficiency using a high throughput screening method and a trial of oral S-adenosyl-L-methionine as a treatment method. Dev Med Child Neurol 2013;55:1060– 1064.
Marie S, Flipsen JWAM, Duran M et al. Prenatal diagnosis in adenylosuccinate lyase deficiency. Prenat Diagn 2000;20:33-36
Jureccka A, Tylki-Szymanska A, Zikanova M et al. d-Ribose therapy in four Polish patients with adenylosuccinate lyase deficiency: absence of positive effect. J Inherit Metab Dis 2008;31:548
Jurecka A, Opoka-Winiarska V, Rokicki D, Tylki-Szymanska A. Neurologic presentation, diagnostics, and therapeutic insights in a severe case of adenylosuccinate lyase deficiency. J Child Neurol 2012;27:645–649.
Marie S, Heron B, Bitoun P et al. AICA-Ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Am J Hum Genet 2004;74:1276-1281.
Ramond F, Rio M, Héron B et al. AICA-ribosiduria due to ATIC deficiency: Delineation of the phenotype with three novel cases, and long-term update on the first case. J Inherit Metab Dis. 2020;43(6):1254-1264.
Fishbein WN, Armbrustmacher VW, Griffin JL Myoadenylate deaminase deficiency: a new disease of muscle. Science 1978; 200:545-548.
Lim L, Palayer M, Bruneau A et al. Myoadenylate deaminase deficiency: a frequent cause of muscle pain A case detected by exercise testing. Ann Biol Clin (Paris). 2017;75(4):445-449.
Jinnah HA, Sabina RL, Van Den Berghe G. Metabolic disorders of purine metabolism affecting the nervous system. Handb Clin Neurol. 2013;113:1827-1836.
Vockley J, Rinaldo P, Bennett MJ et al. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol Genet Metab 2000;71:10-18.
Ogasawara N, Goto H, Yamada Y et al. Deficiency of AMP deaminase in erythrocytes. Hum Genet 1987;75:15-18.
Sabina RL, Fishbein WN, Pezeshkpour G et al. Molecular analysis of the myoadenylate deaminase deficiencies. Neurology 1992;42:170–179.
Zöllner N, Reiter S, Gross M et al. Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose. Klin Wochenschr 1986;64:1281
Flinn AM, Gennery AR. Adenosine deaminase deficiency: a review. Orphanet J Rare Dis. 2018;13(1):6
Hershfield M. Adenosine deaminase deficiency. In: Pagon RA, Bird TD, Dolan CR, Stephens K (eds) GeneReviews [Internet]. Seattle (WA) University of Washington, Seattle; 1993-2006 Oct 03 [updated 2009 Jul 14]
Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. Notarangelo LD, Grunebaum E.J Allergy Clin Immunol. 2019;143(3):852-863.
Aiuti A, Cattaneo F, Galimberti S et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency N Engl J Med 2009;360:447-458.
Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fisher A. Gene therapy for severe combined immunodeficiency. Annu Rev Med 2005;56:585-602.
Kohn DB. Update on gene therapy for immune deficiencies. Clin Immunol 2010;135:247-254.
Wadman SK, Duran M, Beemer FA et al. Absence of hepatic molybdenum cofactor: an inborn error of metabolism leading to a combined deficiency of sulphite oxidase and xanthine dehydrogenase. J Inherit Metab Dis 1983;6 [1]:78-83.
Claerhout H, Witters P, Régal L, Jansen K et al. Isolated sulfite oxidase deficiency. J Inherit Metab Dis. 2018;41(1):101-108.
Mendel RR, Bittner F. Cell biology of molybdenum. Biochim Biophys Acta 2006;1763:621-635
Peretz H, Korostishevsky M, Steinberg DM et al. An ancestral variant causing type I xanthinuria in Turkmen and Arab families is predicted to prevail in the Afro-Asian stone-forming belt. JIMD Rep. 2019;51(1):45-52.
Yamamoto T, Moriwaki Y, Takahashi S et al. Identification of a new point mutation in the human molybdenum cofactor sulferase gene that is responsible for xanthinuria type II. Metabolism 2003;52:1501-1504.
Reiss J, Johnson JL. Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH. Hum Mutat 2003;21:569-576.
Arenas M, Fairbanks LD, Vijayakumar K et al. An unusual genetic variant in the MOCS1 gene leads to complete missplicing of an alternatively spliced exon in a patient with molybdenum cofactor deficiency. J Inherit Metab Dis 2009;32:560-569.
Veldman A, Santamaria-Araujo JA, Sollazzo S et al. Successful treatment of molybdenum cofactor deficiency type A with pCMP. Pediatrics 2010;125:1249-1254.
Harris JC. Lesch-Nyhan syndrome and its variants: examining the behavioral and neurocognitive phenotype. Curr Opin Psychiatry. 2018;31(2):96-102.
Jinnah HA, Visser JE, Harris JC et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006;129:1201-1217.
Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48
Jinnah HA, Ceballos-Picot I, Torres RJ et al. Attenuated variants of Lesch-Nyhan disease. (Lesch-Nyhan Disease International Study Group) Brain 2010;133:671-689.
Cristini S, Navone S, Canzi L, et al. Human neural stem cells: a model system for the study of Lesch-Nyhan disease neurological aspects. Hum Mol Genet. 2010;19(10):1939-1950.
Guibinga GH, Hsu S, Friedmann T. Deficiency of the house-keeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) dysregulates neurogenesis. Mol Ther 2010;18:54-62.
Nyhan WL, O’Neill JP, Harris JC, Jinnah HA (2009) Lesch-Nyhan syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K eds) GeneReviews [Internet]. University of Washington, Seattle; 1993- 2000 Sep 25 [updated 2010 Jun 10]
Jinnah HA, De Gregorio L, Harris JC et al. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res 2000; 463:309-326.
Kaufman JM, Greene ML, Seegmiller JE. Urine uric acid to creatinine ratio – a screening test for inherited disorders of purine metabolism. Phosphoribosyl-transferase (PRT) deficiency in X-linked cerebral palsy and in a variant of gout. J Pediatr 1968;73:583-592.
Seegmiller JE, Rosenbloom FM, Kelley WN. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science 1967;155:1682-1684.
Bell S, Kolobova I, Crapper L, Ernst C. Lesch-Nyhan Syndrome: Models, Theories, and Therapies. Mol Syndromol. 2016;7(6):302-311.
Mandel H, Szargel R, Labay V et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001;29:337-341.
Dimmock DP, Dunn JK, Feigenbaum A et al. Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency. Liver Transplant 2008; 14:1480-1485.
Bulst S, Abicht A, Holinksi-Feder E et al. In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. Hum MolGenet 2009;18:1590
Balasubramaniam S, Duley JA, Christodoulou J Inborn errors of pyrimidine metabolism: clinical update and therapy. J Inherit Metab Dis. 2014;37(5):687-698.
Fidai SS, Sharma AE, Johnson DN, Segal JP, Lastra RR. Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity. Autops Case Rep. 2018;8(4):e2018049.
Kuilenburg v ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-950.
Fleger M, Willomitzer J, Meinsma R et al. Dihydropyrimidine Dehydrogenase Deficiency: Metabolic Disease or Biochemical Phenotype? JIMD Rep. 2017;37:49-54.
Gennip v AH, Driedijk PC, Elzinga A, Abeling NGGM. Screening for defects of dihydropyrimidine degradation by analysis of amino acids in urine before and after acid hydrolysis. J Inherit Metab Dis 1992;15:413-415.
Kuilenburg v ABP, Dobritzsch D, Meijer J et al. Dihydropyrimidinase deficiency: phenotype, genotype and structural consequences in 17 patients. Biochim Biophys Acta 2010;1802:639-648.
Hamajima N, Kouwaki M, Vreken P et al. Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene. Am J Hum Genet 1998;63:717-726.
van Kuilenburg AB, Dobritzsch D, Meijer J et al. ßureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochim Biophys Acta 2012;1822(7):1096–1108.
Assmann B, Göhlich G, Baethman M et al. Clinical findings and a therapeutic trial in the first patient with beta-ureido-propionase deficiency. Neuropediatrics 2006;37:20-25.
Kuilenburg v AB, Meinsma R, Beke E et al. Beta-ureido-propionase deficiency: an inborn error or pyrimidine degradation associated with neurological abnormalities. Hum Mol Genet 2004;13:2793-2801.
Yaplito-Lee J, Pitt J, Meiijer J et al. Beta-ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems. Mol Genet Metab 2008;93:190-194.
Assmann BE, Kuilenburg v AB, Distelmaier F et al. Beta-ureidopopionase deficiency presenting with febrile status epilepticus. Epilepsia 2006; 47:215-217.
Kuhara T, Ohse M, Inoue Y, Shinka T. Five cases of ß-ure-idopropionase deficiency detected by GC/MS analysis of urine metabolome. J Mass Spectrom 2009;44:214-221.
Zanella A, Bianchi P, Fermo E, Valentini G. Hereditary pyrimidine 5’-nucleotidase deficiency: from genetics to clinical manifestations. British J Haemat 2006;133:113-123.
Saada A, Shaag A, Mandel H et al. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2011; 29:342-344.
Oskoui M, Davidzon G, Pascual J et al. Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. Arch Neurol 2006; 63:1122-1126.
Lesko N, Naess K, Wibom R et al. Two novel mutations in thymidine kinase-2 cause early onset fatal encephalomyopathy and severe mtDNA depletion. Neuromuscul Disord 2010;20:198-203.
